A VIABLE CELL POPULATION, METHOD FOR PRODUCTION AND USES THEREOF

The present disclosure relates to a viable cell population, a method for production and uses thereof. The viable cell population of the present disclosure can be used in medicine, in particular in a method for the treatment of cancer, immune diseases, or viral or bacterial infections. This disclosur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DE JESUS MATOS, Maria Teresa, FIGUEIREDO GONÇALVES, Márcia, VAN KOOYK, Yvette, COSTA DE CARVALHO MARQUES, Graça Susete, ARAUJO ALVES MARTINS DA SILVA, Mariana, SANTOS FERNANDES FERRO, Tiago João, TADOKORO, Carlos Eduardo, DE BARROS MONTEIRO, Mauro André, CORDEIRO DA SILVA, Zélia Maria, QUINTELA VIDEIRA, Paula Alexandra, VAN VLIET, Sandra Johanna
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure relates to a viable cell population, a method for production and uses thereof. The viable cell population of the present disclosure can be used in medicine, in particular in a method for the treatment of cancer, immune diseases, or viral or bacterial infections. This disclosure may also be suitable for cellular vaccine development. The viable cell population now disclosed has low sialic acid content, is loaded with specific antigens, shows higher antigen presentation, high maturation and co-stimulatory properties, and less tolerogenic properties. The present disclosure relates to a population of viable cells, wherein said population is obtainable by the maturation of the dendritic cells or T2 cells treated with sialidase during 45 min - overnight at 37 °C and, wherein the sialidase concentration vary between 0.002 U/mL - 0.005 U/mL per 1x106 of dendritic cells or T2 cells.